Older People With Chronic Leukemia May Benefit From Experimental AgentThe experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J...
Trial Of ALK Inhibitor In Neuroblastoma, LymphomaA pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma...
The Cause Identified Of LGL LeukemiaLGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease...
Using Antioxidants To Stabilize Fanconi AnemiaFanconi anemia (FA) is a rare genetic disorder which affects one person in 350,000. People affected by this disease have defects in DNA repair, and are hypersensitive to oxidative damage, resulting in bone marrow failure and an increased predisposition to cancer...
Specific Clinical Guidance Urgently Needed On Bone Cancer Drugs Although bisphosphonate drugs can reduce pain and bone fractures in individuals with multiple myeloma, no one drug is superior, according to a systematic review of the current evidence of these drugs. The review is published in The Cochrane Library. Multiple myeloma is a type of cancer that grows in and on bones. The disease can cause fractures in the spine and long bones...
Clinical Guidance Remains Non-Specific For Drugs To Reduce Bone Cancer DamageBone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma...
Revlimid (Lenalidomide) For Myeloma - Phase III Study Findings An evaluation of lenalidomide's (Revlimid) long-term 'maintenance' efficacy for patients with multiple myeloma has demonstrated considerable improvements from the time to progression and overall survival for those suffering from this often-fatal form of hematologic cancer. The May 10 issue of the New England Journal of Medicine reports that Dr. Philip L...
Identification Of A MicroRNA Prognostic Marker In Acute LeukemiaA study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes(CN-AML). The study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J...
New Maintenance Therapy Benefits Patients With Multiple MyelomaMultiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients...
![](\"http://www.igotyourindex.com/igyindex.gif?DOCUMENTNAME=&DOCUMENTLINK=&GOALNAME&=DOCUMENTVALUE&=GROUPNAME\")